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Abstract
Introduction: This study investigated five confirmed rheumatoid arthritis (RA) susceptibility genes/loci (HLA-DRB1, 
PTPN22, STAT4, OLIG3/TNFAIP3 and TRAF1/C5) for association with susceptibility and severity in an inception cohort.
Methods: The magnitude of association for each genotype was assessed in 1,046 RA subjects from the Yorkshire Early 
RA cohort and in 5,968 healthy UK controls. Additional exploratory subanalyses were undertaken in subgroups defined 
by autoantibody status (rheumatoid factor and anti-cyclic citrullinated peptide) or disease severity (baseline articular 
erosions, Health Assessment Questionnaire (HAQ) score and swollen joint count (SJC)).
Results: In the total RA inception cohort, the HLA-DRB1 shared epitope (per-allele odds ratio (OR) = 2.1, trend P < 
0.0001), PTPN22 (per-allele OR = 1.5, trend P < 0.0001), OLIG3/TNFAIP3 locus (per-allele OR = 1.2, trend P = 0.009) and 
TRAF1/C5 locus (per-allele OR = 1.1, trend P = 0.04) were associated with RA. The magnitude of association for these loci 
was increased in those patients who were autoantibody-positive. PTPN22 was associated with autoantibody-negative 
RA (per-allele OR = 1.3, trend P = 0.04). There was no evidence of association between these five genetic loci and 
baseline erosions or SJC in the total RA cohort, after adjustment for symptom duration. TRAF1/C5 was significantly 
associated with baseline HAQ, however, following adjustment for symptom duration (P trend = 0.03).
Conclusions: These findings support the mounting evidence that different genetic loci are associated with 
autoantibody-positive and autoantibody-negative RA, possibly suggesting that many of the genes identified to date 
are associated with autoantibody production. Additional studies with a specific focus on autoantibody-negative RA will 
be needed to identify the genes predisposing to this RA subgroup. The TRAF1/C5 locus in particular warrants further 
investigation in RA as a potential disease severity locus.
Introduction
Rheumatoid arthritis (RA) [MIM 180300] is a phenotypi-
cally heterogeneous, chronic destructive inflammatory
disease of synovial joints, with an estimated prevalence of
0.8% in the UK [1]. A strong genetic component has been
determined with heritability estimates of 50 to 60% from
twin studies, with up to an additional 50% contribution
from environmental and/or physiological risk factors [2].
Approximately 40% of genetic susceptibility to RA is
accounted for by the HLA-DRB1 alleles encoding the
shared epitope (SE), the major RA susceptibility locus [3],
together with the protein tyrosine phosphatase nonre-
ceptor 22 gene (PTPN22), a second susceptibility gene
confirmed in populations of northern European ancestry
[4]. Recent genome-wide association studies and candi-
date gene studies in RA have been highly successful in
both the confirmation of known genetic associations and
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warrant further investigation [5]. The present study
focuses on five confirmed RA susceptibility genes/loci -
HLA-DRB1 (6p21), PTPN22 (1p13), OLIG3/TNFAIP3
(6q23), STAT4 (2q32) and TRAF1/C5 (9q33) - that are
associated with RA with low-to-moderate risk in UK
patients [6-8]. Some of these loci have been replicated in
other Caucasian populations of northern European
descent (reviewed in [5,9]), although only HLA-DRB1 SE
and STAT4 have been confirmed in Asian populations
[10-12].
RA is characterised by the presence of autoantibodies
(rheumatoid factor (RF) and cyclic citrullinated peptide
(CCP) antibodies) in a significant majority of patients.
Many of the RA susceptibility genes identified to date
appear to only be significant in the autoantibody-positive
cohorts, although this may be secondary to the increased
statistical power in this more prevalent patient subgroup
[13]. If confirmed, this observation may suggest that
these loci are influencing susceptibility to autoantibody
production, perhaps through the loss of self-tolerance,
thus explaining their association with multiple autoim-
mune disorders. The challenge over the next few years
will be to identify whether these genes also influence the
inflammatory process in RA per se. Unravelling the stage
in the disease process in which these genes exert their
maximum influence on RA pathogenesis will be neces-
sary to fully unveil their clinical significance and reveal
those pathways that are potential therapeutic targets or
may become clinically useful biomarkers.
In the present study we sought to identify which parts
of the RA pathway were affected by these susceptibility
genes by studying an RA inception cohort from the UK.
The Yorkshire Early Arthritis Register (YEAR) Consor-
tium has made a considerable effort to review all patients
presenting with early inflammatory symptoms within the
community through the establishment of a rapid access
system. This enables the full spectrum of RA to be stud-
ied. Confirmation of association in this cohort of newly
diagnosed RA would support a contribution of these loci
to RA susceptibility per se rather than disease persistence
and severity, which potentially confound assessment of
genetic susceptibility in cross-sectional secondary care
cohorts. Further analyses, albeit at reduced statistical
power, would determine whether the association is
observed within both the autoantibody-positive (RF or
CCP) and the autoantibody-negative (RF or CCP) sub-
groups, to determine whether the primary association
was with autoantibody-positive disease. These two anti-
bodies are highly correlated and much larger cohorts
would be required to tease out antibody-specific effects.
We then sought to examine the influence of these loci
on disease severity. Analysis of RA severity following the
initiation of therapy is fraught with many difficulties
since the physician's choice of medication, dose pre-
scribed, toxicities, co-morbidities and psychosocial fac-
tors may all influence treatment outcome and persistence
of inflammation. We therefore took advantage of our
rapid access referral system to assess the influence of
these loci on objective markers of joint inflammation
(swollen joint count (SJC)), function (Health Assessment
Questionnaire (HAQ)) and a measure of articular damage
(erosions on plain radiographs of the hands and feet) at
RA diagnosis. Although these secondary severity analyses
would be of lower statistical power and require replica-
tion, we propose that any positive results would reveal
those pathophysiological pathways that warrant further
investigation to see whether they can be exploited as
potential therapeutic targets and prognostic and/or pre-
dictive biomarkers that may ultimately guide therapeutic
decisions.
Materials and methods
Sample collections
The YEAR network made a considerable effort to review
all patients presenting with early inflammatory joint
symptoms to ensure that the full spectrum of established
RA could be studied. All cases fulfilled the 1987 Ameri-
can College of Rheumatology classification criteria for
RA (n = 1,046), were Caucasian of Northern European
descent, 18 years of age or older at disease onset and had
a disease duration of less than 3 months (inception
cohort). Comprehensive and standardised clinical docu-
mentation was undertaken for all patients at baseline.
Radiographs of the hands and feet were obtained at pre-
sentation. The presence or absence of articular erosions,
using standard clinical criteria, was documented by a
radiologist at the treating hospital. Healthy controls (n =
5,968) were recruited from five centres in the UK, as
described previously [8]. All participants were recruited
after providing informed consent and the study was
approved by the Multi-Centre Research Ethics Commit-
tee.
Immunoassays
RA cases were recruited from NHS Rheumatology Clin-
ics and the IgM RF status was measured using standard
nephelometric assays. Patients who had ever had a titre ≥
40 units/ml were defined as RF-positive. The presence of
IgG CCP antibodies was documented at a single time
point for a proportion of the patients (n = 619), using the
commercially available DIASTAT™ anti-CCP ELISA
(Axis-Shield Diagnostics Limited, Kimbolton, UK) or the
ELiA CCP kit on an ImmunoCAP 100 (Phadia AB, Upp-
sala, Sweden). Patients who had a titre ≥ 5.5 units/ml or ≥
10 units/ml for the two assays, respectively, were defined
as CCP-positive.
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HLA-DRB1*01-16 types were determined at each centre
using commercially available semi-automated PCR
sequence-specific oligonucleotide probe typing tech-
niques, as previously described [8]. In a subgroup of RA
subjects, HLA-DRB1 typing was undertaken using a
research assay based on PCR sequence-specific oligonu-
cleotide probe linear array technology, developed by
Roche Molecular Systems, Inc. (Pleasanton, CA, USA).
PCR products amplified with biotinylated primers were
denatured and hybridised to an immobilised probe array.
Labelled PCR products hybridised to specific probes
were detected using streptavidin-horseradish peroxidase
and a chromogenic substrate. The probe binding pattern
for each sample was scanned and the HLA-DRB1 geno-
type was assigned by the inhouse software StripScan. The
HLA-DRB1 SE susceptibility sequences were defined as
those encoding the amino acids LQKAA, LQRAA and
LRRRA at positions 67, 70, 71, 73 and 74 in the third
hypervariability region, and included HLA-DRB1*0101,
HLA-DRB1*0102, HLA-DRB1*0401, HLA-DRB1*0404,
HLA-DRB1*0405, HLA-DRB1*0408 and HLA-
DRB1*1001.
Genotyping of the PTPN22, OLIG3/TNFAIP3, STAT4
and TRAF1/C5 loci was undertaken using the Sequenom
MassArray platform, as described previously [6-8]. Geno-
typing was undertaken sequentially and these samples
comprised a subgroup of the RA cases recruited by the
UK Rheumatoid Arthritis Genetics (UKRAG) Consor-
tium. For each individual plex, only those DNA samples
with >90% success rate for all SNPs and those SNPs with
>95% success rates across all samples passed the quality
control step and were included in subsequent analyses.
For some samples, inadequate DNA was available to
enable inclusion in all plexes for this study. Some addi-
tional PTPN22 typing was undertaken using multi-locus
SNP genotyping, whereby PCR products were hybridised
to a linear probe array panel, which was developed by
Roche Molecular Systems, Inc. Duplicate genotyping data
were available for PTPN22 for >600 samples that corre-
sponded perfectly, thus validating the latter assay. For
each of the four non-MHC loci, the most significantly
associated SNP identified to date in the UK population
was tested (PTPN22 [rs2476601], OLIG3/TNFAIP3 locus
[rs6920220], STAT4 [rs7574865] and TRAF1/C5 locus
[rs10760130]).
Analysis
Statistical analyses were performed using the SPSS 13.0
statistical package for Windows, (Chicago, IL, USA).
Genotype frequencies were initially compared using 3 × 2
tables followed by a trend test, which performs well under
either additive, dominant or recessive models. This is
asymptotically equivalent to logistic or linear regression
based on allele count (0,1,2). Two-sided P < 0.05 values
are highlighted, although positive findings should be con-
sidered in light of the number of statistical tests under-
taken and further studies in additional inception cohorts
will be required to confirm these findings. The data were
further stratified according to the presence of autoanti-
bodies (RF and/or CCP). Subjects were grouped into
autoantibody (RF or CCP)-positive and autoantibody-
negative (RF and CCP) cohorts. Those individuals only
positive for only a single antibody (RF+CCP- and RF-
CCP+) were thus coded as autoantibody-positive. Where
data were only available for a single antibody (n = 445),
those subjects were included in the autoantibody-positive
or autoantibody-negative cohorts based on the data avail-
able. In the analysis of disease susceptibility, odds ratios
(OR) and their 95% confidence intervals were calculated;
the per-allele ORs are shown unless otherwise stated. The
severity analyses were undertaken in a subgroup of
patients where the symptom duration was known and
<24 months. Logistic (presence/absence of erosions) and
linear regression (SJC, HAQ) were used to undertake
trend tests of association, which were adjusted for symp-
tom duration.
Results
The aim of the current study was to determine whether
the previously reported RA susceptibility genes/loci
(HLA-DRB1, PTPN22, OLIG3/TNFAIP3, STAT4 and
TRAF1/C5) were associated with RA in an inception
cohort. Additional exploratory subanalyses were under-
taken to explore whether any positive findings were asso-
ciated with a specific subgroup defined by autoantibody
status or disease severity (baseline articular erosions, SJC
and HAQ).
Characteristics of the RA patients and controls
The RA cohort comprised 1,046 early RA patients, of
whom 67% were female, 65% were RF-positive (n = 970),
63% were anti-CCP-positive (n = 619) and 70% of 968
subjects were HLA-DRB1 SE-positive. The disease char-
acteristics of the total RA cohort and the autoantibody-
positive (RF or CCP) and autoantibody-negative (RF and
CCP) cohorts are presented in Table 1.
Association of HLA-DRB1 SE, PTPN22, OLIG3/TNFAIP3, STAT4 
and TRAF1/C5 with RA susceptibility
In the total RA inception cohort (n = 1,046), an initial
model-free analysis of genotype frequencies was per-
formed by undertaking a 3× 2 analysis. The global P val-
ues for each genetic locus are as follows: HLA-DRB1 SE
alleles, P < 1 × 10-6 (n = 968); PTPN22, P = 2 × 10-6 (n =
855); OLIG3/TNFAIP3, P = 0.030 (n = 810); STAT4, P =
0.035 (n = 767); and TRAF1/C5, P = 0.041 (n = 763).
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across all three genotypes; the ORs (95% confidence
intervals) shown are per copy of the HLA-DRB1 SE or per
copy of the minor allele for the remaining loci (Table 2).
Thus, HLA-DRB1 SE alleles (OR = 2.1 (1.9 to 2.4), P <
0.0001), PTPN22 (OR = 1.5 (1.3 to 1.8), P < 0.0001),
OLIG3/TNFAIP3 (OR = 1.2 (1.0 to 1.4), P = 0.009) and
TRAF1/C5 (OR = 1.1 (1.0 to 1.3), P = 0.035) were associ-
ated with RA. The magnitude of association for these loci
was increased in those patients who were autoantibody-
positive (HLA-DRB1 SE, OR = 2.9 (2.5 to 3.3), P < 0.0001;
PTPN22, OR = 1.6 (1.3 to 1.9), P < 0.0001; OLIG3/
TNFAIP3, OR = 1.3 (1.1 to 1.5), P < 0.0001; and TRAF1/
C5, OR = 1.2 (1.0 to 1.3), P = 0.043), with weak evidence
of association for STAT4 (OR = 1.2 (1.0 to 1.4), P = 0.048)
in this subgroup. The size of the autoantibody-negative
cohort was limited (n = 298), resulting in lower statistical
power - although a significant association was observed
with PTPN22 (OR = 1.3 (1.0 to 1.7), P = 0.039). There was
no evidence, however, of association for the HLA-DRB1
SE (OR = 1.1 (0.9 to 1.4), P = 0.279), or for the OLIG3/
TNFAIP3 (OR = 0.9 (0.7 to 1.2), P = 0.578), STAT4 (OR =
1.1 (0.9 to 1.4), P = 0.266) or TRAF1/C5 (OR = 1.1 (0.9 to
1.3), P = 0.392) loci in autoantibody-negative disease. A
statistically significant difference in the genotype fre-
quencies between the autoantibody-positive and autoan-
tibody-negative cohorts was observed for HLA-DRB1 SE
(trend P < 0.001) and OLIG3/TNFAIP3 (trend P = 0.008),
but not for PTPN22 (trend P = 0.2), STAT4 (trend P = 0.8)
or TRAF1/C5 (trend P = 0.6).
Association of HLA-DRB1 SE, PTPN22, OLIG3/TNFAIP3, STAT4 
and TRAF1/C5 with RA severity
In view of the potential importance of symptom duration
on disease severity measures at baseline, the severity
analyses were undertaken in a subgroup of 666 individu-
als for whom the symptom duration had been recorded
and was <24 months, to allow adjustment for symptom
duration in the regression models.
Prevalent erosions were observed in 21.5% of 615 sub-
jects at presentation and were associated with symptom
duration (P = 0.011), but not with SJC (P = 0.96, n = 595),
RF (P = 0.21, n = 580) or CCP (P = 0.19, n = 428). Like-
wise, SJC was associated with symptom duration (P <
0.001, n = 666), but not RF (P = 0.07, n = 623) or CCP (P =
0.15, n = 459). Finally, HAQ was associated with symp-
tom duration (P = 0.001, n = 666) but not with CCP (P =
0.66, n = 480), with only a weak trend toward significance
for RF (P = 0.05, n = 633). There was no evidence that
HLA-DRB1 SE, PTPN22, OLIG3/TNFAIP3, STAT4 or
TRAF1/C5 were significantly associated with prevalent
Table 1: Clinical characteristics of rheumatoid arthritis cases
Total RA cohort (n = 1,046) Autoantibody-positive RA 
(n = 692)
Autoantibody-negative RA 
(n = 325)
Number of 
valid subjects
Summary Number of 
valid subjects
Summary Number of 
valid subjects
Summary
Age (years) 926 59 (14) 411 57 (13) 183 60 (14)
Gender 
(female)
1046 702 (67%) 692 468 (68%) 325 210 (65%)
Rheumatoid 
factor-positive
970 628 (65%) 667 628 (94%) N/A N/A
Cyclic 
citrullinated 
peptide-
positive
619 389 (63%) 445 389 (87%) N/A N/A
Erosions at 
baselinea
607 132 (22%) 421 95 (23%) 186 37 (28%)
Swollen joint 
count at 
baselinea
648 9.7 (6.2 to 
10.2)
447 9.3 (8.8 to 9.9) 186 10.8 (9.8 to 
11.8)
Health 
Assessment 
Questionnaire 
at baselinea
648 1.33 (1.27 to 
1.39)
447 1.35 (1.28 to 
1.42)
186 1.30 (1.19 to 
1.41)
Data presented as mean (standard deviation), n (%) or mean (95% confidence interval). N/A, not applicable; RA, rheumatoid arthritis. 
aSubgroup of individuals with documented symptom duration <24 months.
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cohort, after adjustment for symptom duration (Table 3).
There was also no evidence of association between
these five genetic loci with SJC, after adjustment for
symptom duration in linear regression analyses of the
total RA cohort (Table 3). The TRAF1/C5 locus, however,
was significantly associated with HAQ, following adjust-
ment for symptom duration (P = 0.031, n = 468). It is
important to note that raw P values have been presented
throughout. These findings should therefore be consid-
ered in light of the number of statistical tests undertaken
in the analysis of RA severity, and further larger studies
will be required to substantiate these findings. If a strict
Bonferroni correction was applied for the severity analy-
ses, the level of significance would be set at P < 0.003; and
for the combined susceptibility and severity studies, the
level would be set at P < 0.002.
Discussion
In the present study we confirmed that the HLA-DRB1
SE, PTPN22 and the OLIG3/TNFAIP3 and TRAF1/C5
loci were associated with susceptibility to RA in an incep-
Table 2: Genotype frequencies in rheumatoid arthritis, and in autoantibody-positive/autoantibody-negative rheumatoid 
arthritis, relative to controls
RA cohort Controls, 
n (%)
Cases,
n (%)
Per-allele 
OR (95% 
CI)
P 
trend
Autoanti
body-
positive 
RA
Per-allele 
OR (95% 
CI)
P 
trend
Autoanti
body-
negative 
RA
Per-allele 
OR (95% 
CI)
P 
trend
HLA-DRB1 
shared epitope
n = 1,351 n = 968 n = 643 n = 298
Negative 717 (53.1) 290 (30.0) 138 (21.5) 144 (48.3)
One copy 517 (38.3) 475 (49.1) 2.12 (1.87 
to 2.40)
<0.0001 332 (51.6) 2.85 (2.46 
to 3.29)
<0.0001 129 (43.3) 1.11 (0.92 
to 1.35)
0.279
Two 
copies
117 (8.7) 203 (21.0) 173 (26.9) 25 (8.4)
PTPN22 
(rs2476601)
n = 3,492 n = 855 n = 572 n = 259
GG 2,817 (80.7) 624 (73.0) 413 (72.2) 195 (75.3)
GA 635 (18.2) 212 (24.8) 1.50 (1.28 
to 1.75)
<0.0001 144 (25.2) 1.56 (1.31 
to 1.87)
<0.0001 60 (23.2) 1.32 (1.01 
to 1.72)
0.039
AA 40 (1.1) 19 (2.2) 15 (2.6) 4 (1.5)
OLIG3/TNFAIP3 
(rs6920220)
n = 3,478 n = 810 n = 545 n = 242
GG 2,146 (61.7) 464 (57.3) 294 (53.9) 155 (64.0)
GA 1,197 (34.4) 303 (37.4) 1.19 (1.04 
to 1.35)
0.009 220 (40.4) 1.32 (1.14 
to 1.54)
<0.0001 77 (31.8) 0.94 (0.74 
to 1.18)
0.578
AA 135 (3.9) 43 (5.3) 31 (5.7) 10 (4.1)
STAT4 
(rs7574865)
n = 3,520 n = 767 n = 515 n = 234
GG 2,151 (61.1) 451 (58.8) 294 (57.1) 143 (61.1)
GT 1,208 (34.3) 264 (34.4) 1.14 (1.00 
to 1.29)
0.054 190 (36.9) 1.17 (1.00 
to 1.36)
0.048 70 (29.9) 1.13 (0.91 
to 1.41)
0.266
TT 161 (4.6) 52 (6.8) 31 (6.0) 21 (9.0)
TRAF1/C5 
(rs10760130)
n = 3,506 n = 763 n = 512 n = 233
AA 1,096 (31.3) 224 (29.4) 151 (29.5) 69 (29.6)
GA 1,742 (49.7) 363 (47.6) 1.13 (1.01 
to 1.26)
0.035 238 (46.5) 1.15 (1.00 
to 1.31)
0.043 114 (48.9) 1.09 (0.90 
to 1.31)
0.392
GG 668 (19.1) 176 (23.1) 123 (24.0) 50 (21.5)
CI, confidence interval; OR, odds ratio; RA, rheumatoid arthritis.
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total UKRAG cohort (HLA-DRB1 SE (2.1, 2.6), PTPN22
(1.5, 1.5), OLIG3/TNFAIP3 (1.2, 1.2) and TRAF1/C5 loci
(1.1, 1.1); early RA compared with total UKRAG cohort
[6-8,14], respectively). The distinction between suscepti-
bility and severity remains difficult and some may argue
that the present study still does not sample the full spec-
trum of RA observed in the community. We believe, how-
ever, these findings do support a genuine association with
RA susceptibility. Further studies utilising community-
based cohorts will ultimately be required to confirm
these findings. Of particular interest is the observation
that for each of these loci the association was most
marked in the autoantibody-positive subgroup and,
although the association with STAT4 was not confirmed,
some evidence of a weak association was observed in the
subgroup harbouring autoantibodies. Indeed, only
PTPN22 demonstrated any suggestion of association with
RA in the autoantibody-negative cohort, which warrants
further investigation in a larger inception cohort.
These findings support the mounting evidence that dif-
ferent genetic loci are associated with autoantibody-posi-
tive and autoantibody-negative RA. Many of the genes
identified to date may therefore predispose to autoimmu-
nity in general, or more specifically the immunological
processes involved in the breakdown of self-tolerance and
autoantibody production. This is supported by the asso-
ciation of PTPN22 and the OLIG3/TNFAIP3 locus with
other autoantibody-associated autoimmune diseases,
such as systemic lupus erythematosus, Graves disease
and type 1 diabetes [5,7,8,15-17], but not with those auto-
immune/inflammatory disorders not associated with
autoantibody production, such as ulcerative colitis,
Crohn's disease and ankylosing spondylitis [5,18,19].
The transcription factor encoded by STAT4 is down-
stream of several cytokines that play a crucial role in the
development of Th1 and Th17 responses, such as IL-12,
IL-15 and IL-23 [20,21] and the type I interferons [21,22].
Whilst this gene undoubtedly contributes to susceptibil-
ity to some autoantibody-associated diseases (RA, sys-
temic lupus erythematosus and type I diabetes), there are
recent reports that it may be associated with both clinical
forms of inflammatory bowel diseases [23] - suggesting
that rather than contributing to autoantibody production,
it may be a common risk factor for inflammatory disease
per se. This is consistent with the apparent association of
STAT4 with both autoantibody-positive and autoanti-
body-negative RA in the literature [7,11,15,23], although
the numbers were considerably lower for the latter sub-
group, in all reported series.
Although we acknowledge there was also reduced
power to detect trends in the autoantibody-negative
cohort in the current study, we were unable to see any
suggestive evidence of association with STAT4, with no
substantive skewing of allele or genotype frequencies.
Additional studies with increased power to investigate
autoantibody-negative RA will be needed to unravel the
genes predisposing to RA in this patient subgroup. Power
calculations based on replicating the association of
PTPN22 with autoantibody-negative disease with an
effect size in the range 1.2 to 1.5 revealed that 2,909 cases
would be required if one control per case was used,
reducing to 2,169 if two controls per case were used. If all
five loci were investigated, the number of autoantibody-
negative cases required would need to increase to 4,329
and 3,227, respectively - with ~12,000 cases required if
the effect size was reduced to 1.1. Such studies will
require a concerted international effort and large-scale
recruitment of cases from around the globe.
In the current study, we analysed the SNPs displaying
the strongest association with RA, after the strongly asso-
ciated HLA-DRB1 SE alleles, in the UK Caucasian popu-
lation [24]. To date, there have been relatively few genetic
loci that have shown consistent association with disease
severity in RA. As stated previously, it is very difficult to
tease out the influence of drugs and other nongenetic fac-
tors when designing these studies. We therefore chose to
investigate these susceptibility loci with objective mark-
ers of joint inflammation or disease severity (radio-
graphic erosions, SJC, and HAQ) at presentation to the
rheumatology department. The presence of radiographic
articular erosions is generally accepted as the most objec-
tive measure of articular damage that is accessible for all
rheumatologists, but there is currently a paucity of stud-
ies investigating this early time point.
In this exploratory study we were unable to find any
strong evidence that these five susceptibility genes were
associated with disease severity measures at baseline. We
found some weak evidence to support the association of
the TRAF1/C5 locus with HAQ at baseline, a marker of
function, although this would not remain significant after
correction for multiple comparisons. Carriers of the
minor A allele of rs10818488 at this locus were previously
shown to have increased radiographic progression, albeit
in a small cohort of 278 CCP-positive individuals [25],
whereas homozygosity for the G allele may be associated
with mortality [26]. We found no evidence, however, that
TRAF1/C5 was associated with erosions in this cohort. It
is important to note that due to a high level of linkage dis-
equilibrium between the genes encoding TNF receptor-
associated factor 1 and complement component 5, it is
currently not possible to unravel which of these two
genes at 9q33.2 harbours the causal variant. Both are
excellent candidate genes that may perpetuate chronic
inflammation in RA. TNF receptor-associated factor 1 is
a negative regulator of TNF receptor and Toll-like recep-
tor signalling, and may contribute to the proliferation of
T cells, and the complement pathway may directly con-
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Table 3: Association with disease severity measures in early rheumatoid arthritis and in autoantibody-positive/antibody-
negative disease
RA cohort Erosions Swollen joint count Health Assessment Questionnaire
Erosive,
n (%)
Per-allele 
OR (95% 
CI)
P trend 
adj.a
Mean 
(95% CI)
Coefficient 
(95% CI)
P trend 
adj.a
Mean 
(95% CI)
Coefficient 
(95% CI)
P trend 
adj.a
HLA-DRB1 
shared epitope
554 (21.5) n = 587 n = 587
Negative 175 (22.9) 0.88 0.398 10.5 (9.5 to 
11.5)
-0.03 0.455 1.35 (1.24 to 
1.47)
-0.00 0.965
One copy 278 (20.9) (0.65 to 
1.19)
9.4 (8.7 to 
10.1)
(-1.04 to 
0.47)
1.38 (1.29 to 
1.46)
(-0.09 to 
0.09)
Two 
copies
101 (20.8) 9.7 (8.4 to 
11.0)
1.27 (1.14 to 
1.41)
PTPN22 
(rs2476601)
580 (20.7) n = 468 n = 468
GG 423 (22.0) 0.75 0.189 9.5 (8.8 to 
10.2)
-0.02 0.593 1.32 (1.23 to 
1.40)
0.06 0.133
GA 147 (17.0) (0.48 to 
1.16)
9.0 (7.8 to 
10.1)
(-1.31 to 
0.75)
1.43 (1.30 to 
1.56)
(-0.03 to 
0.21)
AA 10 (20.0) 10.4 (1.9 to 
18.9)
1.48 (0.35 to 
2.61)
OLIG3/TNFAIP3 
(rs6920220)
551 (20.3) n = 468 n = 468
GG 302 (19.9) 1.03 0.853 9.4 (8.6 to 
10.1)
0.04 0.291 1.36 (1.27 to 
1.45)
-0.01 0.880
GA 217 (20.7) (0.73 to 
1.46)
9.3 (8.3 to 
10.2)
(-0.39 to 
1.31)
1.36 (1.24 to 
1.48)
(-0.11 to 
0.09)
AA 32 (21.9) 10.5 (7.7 to 
13.3)
1.07 (0.76 to 
1.37)
STAT4 
(rs7574865)
476 (20.4) n = 468 n = 468
GG 271 (22.1) 0.82 0.291 9.5 (8.7 to 
10.2)
0.01 0.873 1.38 (1.28 to 
1.47)
-0.06 0.193
GT/ 170 (18.2) (0.57 to 
1.19)
9.3 (8.2 to 
10.3)
(-0.82 to 
0.97)
1.35 (1.23 to 
1.46)
(-0.17 to 
0.04)
TT 35 (17.1) 9.5 (7.0 to 
12.0)
1.12 (0.85 to 
1.39)
TRAF1/C5 
(rs10760130)
474 (20.3) n = 468 n = 468
AA 140 (16.4) 1.18 (0.86 
to 1.61)
0.311 9.7 (8.6 to 
10.8)
-0.03 0.502 1.25 (1.11 to 
1.38)
0.09 0.031
GA 225 (22.7) 9.1 (8.3 to 
9.9)
(-1.07 to 
0.52)
1.34 (1.24 to 
1.43)
(0.01 to 
0.19)
GG 109 (20.2) 9.6 (8.4 to 
10.8)
1.50 (1.35 to 
1.65)
CI, confidence interval; OR, odds ratio; RA, rheumatoid arthritis. aAdjusted for symptom duration (all cases having a symptom duration <24 
months).
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[25,27]. Intensive resequencing efforts with additional
fine-mapping studies in expanded genetic cohorts are
currently underway to identify the disease-associated
variant at such loci. It is likely that for those loci with very
strong and extensive linkage disequilibrium, however,
functional studies may ultimately be required to unravel
the biological significance of the genetic findings.
Conclusions
The importance of studying inception cohorts cannot be
underestimated since most hospital-based cohorts repre-
sent the severe end of the RA spectrum and genetic asso-
ciations derived from such patients cannot discriminate
between susceptibility and severity factors. The present
study supports an association between HLA-DRB1 SE
alleles, PTPN22, OLIG3/TNFAIP3, STAT4 and TRAF1/
C5 with susceptibility to autoantibody-positive RA, but
only the TRAF1/C5 locus was associated with disease
severity in this cohort, although this would no longer
remain significant after correction for multiple compari-
sons. Substantially larger cohorts will ultimately be
required to have adequate power to investigate clinical,
immunological and genetic factors determining disease
severity and response to therapy, and we hope these data
will assist future power calculations. Although the ulti-
mate goal is the development of clinical algorithms that
will facilitate personalised medicine, it also remains
important to identify the immunological and biochemical
pathways that determine outcome, which can then be tar-
geted therapeutically. The TRAF1/C5 locus in particular
warrants further investigation as a potential disease
severity locus in RA.
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